The clinical logic behind the trial rests on a well-documented problem: most patients with hypertension and coexisting ischemic heart disease cannot reach target blood pressure on a single drug. Uncontrolled blood pressure raises the risk of coronary artery disease, heart failure, and stroke by two- to four-fold, and every 20-mmHg rise in systolic pressure roughly doubles the risk of dying from ischemic heart disease. International guidelines from the American College of Cardiology, the American Heart Association, and the European societies of cardiology and hypertension now recommend early combination therapy, ideally in a single pill, particularly for patients at elevated cardiovascular risk. Fixed-dose combinations reduce pill burden, a known driver of poor adherence, while pairing drugs that act through complementary mechanisms.

The combination tested in CONTROL-IHD merges a beta-1 selective beta-blocker with an angiotensin receptor blocker. Metoprolol succinate extended-release blunts the cardiac effects of catecholamines, lowering heart rate, cardiac output, and myocardial oxygen demand, which is why beta-blockers remain central to managing ischemic heart disease. Telmisartan, a long-acting ARB, promotes vasodilation by blocking the renin-angiotensin system and is valued for its prolonged pharmacological action. The formulation employs a proprietary wrap matrix technology, a sustained-release system in which the drug is dispersed within a hydrophilic polymer matrix, designed to deliver uniform drug release over 24 hours, smooth out peak-trough fluctuations, and maintain steady plasma concentrations through the day and night.

The study enrolled 88 adults aged 18 to 65 at seven clinical sites across India. All participants had essential hypertension that remained uncontrolled despite at least four weeks of stable antihypertensive monotherapy, along with stable ischemic heart disease and a resting heart rate above 70 beats per minute. Notably, the investigators chose not to impose a washout period, judging it clinically inappropriate to withdraw background therapy from patients with uncontrolled hypertension and stable ischemic disease. Participants instead received the fixed-dose combination once daily with food for eight weeks, at either 25 mg or 50 mg of metoprolol succinate extended-release paired with 40 mg of telmisartan, with dose up-titration permitted between weeks two and four based on heart rate. In practice, no patient met the predefined criteria for dose adjustment.

The primary endpoint was the change in mean 24-hour systolic blood pressure measured by ambulatory monitoring, and the results were unambiguous. Systolic pressure fell from 143.38 mmHg at baseline to 129.03 mmHg at week eight, a mean reduction of 14.41 mmHg, while diastolic pressure dropped from 88.84 mmHg to 79.34 mmHg, a fall of 9.52 mmHg, both with p-values below 0.0001. Seventy-two patients completed the study, and similar results emerged in both the modified intent-to-treat and per-protocol populations, reinforcing the robustness of the primary analysis. By week eight, the mean 24-hour blood pressure of the group had approached the widely recommended treatment goal of below 130/80 mmHg for patients at elevated cardiovascular risk.

Several secondary findings carry particular technical interest. Ambulatory monitoring identified a responder rate of 36.62 percent, defined as achieving mean 24-hour values below 130/80 mmHg, compared with just 10.67 percent based on office measurements, a disparity that underscores how clinic readings can mask therapeutic response. Blood pressure during the last six hours of the dosing interval, a proxy for early morning control, fell by 15.21 mmHg systolic and 9.85 mmHg diastolic, indicating that the antihypertensive effect was sustained through the period immediately before the next dose, when morning surges typically elevate cardiovascular risk. Mean heart rate declined by roughly 4 to 5 beats per minute, a moderate but clinically relevant reduction in myocardial oxygen demand for patients with ischemic disease, even though few individuals reached the strict target range of 50 to 60 beats per minute.

The study also examined blood pressure variability, an emerging independent predictor of cardiovascular morbidity and mortality, using indices including the smoothness index and the treatment-on variability index. From the weeks two to four visit to week eight, the smoothness index rose by 0.15 for systolic and 0.11 for diastolic pressure, while the treatment-on variability index increased by 0.20 and 0.16 respectively, all statistically significant, reflecting progressively more consistent 24-hour blood pressure lowering. Other variability measures produced mixed signals: weighted standard deviation, average real variability, and delta diastolic pressure showed non-significant downward trends, delta systolic pressure fell significantly, and the coefficient of variation for diastolic pressure increased significantly, a finding the authors flag as warranting further investigation. Overall, the pattern suggests a trend toward a more stable blood pressure profile in selected parameters.

Safety outcomes were favorable. Twenty-one treatment-emergent adverse events were reported by 21 patients, all mild in intensity, with pruritus the most frequent at 5.7 percent. Application-site reactions were attributed to the ambulatory monitoring cuff rather than the oral medication. No serious adverse events, deaths, or discontinuations due to adverse events occurred, and physical examinations, vital signs, and electrocardiograms revealed no significant abnormalities. This tolerability profile is consistent with prior Phase III data on the same combination in Indian patients and supports the drug’s suitability for long-term use.

The authors are candid about the limitations of their design. As an open-label, single-arm study without a comparator, the observed reductions may partly reflect regression toward the mean or a Hawthorne effect from closer monitoring. The predominance of male participants, the enrollment of patients already on monotherapy, and the eight-week follow-up window all constrain generalizability, and endpoints such as target organ damage and hard cardiovascular events were not assessed. Still, the trial is the first in India to evaluate this specific fixed-dose combination using ambulatory monitoring and one of the most comprehensive endpoint analyses in this population. The investigators call for larger, randomized, event-driven trials to confirm whether the sustained blood pressure control demonstrated here translates into reduced strokes, infarctions, and deaths. For now, the study strengthens the case that a single daily pill combining a beta-blocker and an ARB can deliver smooth, round-the-clock blood pressure control for one of cardiology’s most demanding patient groups.

Subject of Research: 24-hour blood pressure control with a metoprolol succinate extended-release and telmisartan fixed-dose combination in patients with essential hypertension and stable ischemic heart disease

Article Title: CONTROL-IHD Study: 24-h BP Control with Metoprolol-Telmisartan FDC in Hypertension and Stable Ischemic Disease

Article References: Sharma, K., Chhaya, G., Chopda, M., Kaul, U., Agarwal, M., Dorairaj, P., Sethuraman, S., Bharathi, P., Dharmadhikari, S., Ahire, P., Khandhedia, C., Markandeywar, N., Mane, A., Mehta, S., & Joglekar, S. (2026). CONTROL-IHD Study: 24-h BP Control with Metoprolol-Telmisartan FDC in Hypertension and Stable Ischemic Disease. Advances in Therapy. https://doi.org/10.1007/s12325-026-03779-x

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03779-x

Keywords: hypertension, ischemic heart disease, fixed-dose combination, metoprolol succinate, telmisartan, ambulatory blood pressure monitoring, blood pressure variability, cardiovascular risk, Phase IV study, combination therapy, CONTROL-IHD, Control

Midlife is a particularly important period for cardiovascular prevention. Biological aging and the menopausal transition can alter blood pressure, metabolism and other risk factors, while physical activity often declines. The researchers focused on women who were insufficiently active and had at least one cardiovascular risk condition, including hypertension or prehypertension, prediabetes or type 2 diabetes, metabolic syndrome, high cholesterol or current smoking. Before joining the study, participants reported less than 90 minutes of moderate-to-vigorous activity per week or fewer than 7,000 steps per day. The group had an average age of 52 and an average body-mass index of 31 kilograms per square meter; 40 percent identified with a racial or ethnic minority group. Although the sample was not designed to represent all women in midlife—many participants had relatively high education and household income—it included a population for whom modest, repeatable changes in daily movement could have meaningful health implications.

The intervention combined techniques drawn from cognitive-behavioral therapy, acceptance and commitment therapy and motivational interviewing. Across six active intervention weeks, coaches introduced nine distinct skills involving behavior, cognition and acceptance. Participants learned to manage time, set goals, solve problems, communicate effectively, draw on partner support, engage with personal values, show willingness to act despite uncomfortable thoughts or feelings, and refocus after a lapse rather than treating it as a relapse. The distinction between a lapse and a relapse was central to the program’s flexible philosophy: missing one walk was not supposed to erase previous progress or trigger all-or-nothing thinking. “Willingness,” in this context, meant choosing a valued behavior even when motivation was low or negative thoughts were present. The researchers paired participants with partners of similar age, baseline activity and availability, allowing them to exchange encouragement between remote meetings with coaches.

The study’s most distinctive feature was its day-by-day measurement. Participants wore either a study-issued pedometer or their own activity tracker and completed an end-of-day survey intended to take no more than five minutes. They recorded their step count, identified the main barrier to physical activity that day and indicated which skills they had used. This intensive approach differs from asking someone at the end of a month how often they exercised, a method vulnerable to imperfect recall and broad, impressionistic answers. Daily reports can connect a person’s experience on a particular day with an objectively recorded behavior, while multilevel statistical models can separate differences between people from fluctuations within the same person. In this analysis, the investigators treated each skill as either used or not used on a given day, then examined how the total number of skills related to steps, barriers and time in the program.

Compliance was high enough to show that this kind of close monitoring is practical. During the intervention and immediate post-intervention period, participants completed 2,186 of the expected 2,600 surveys on time, an 84 percent completion rate that exceeded the researchers’ predefined feasibility threshold of 80 percent. Participants rated the acceptability of reporting daily skill use at an average of 4 out of 5. They rated their confidence in using the skills even higher, at 4.5 out of 5, while the effort required for the program’s daily demands averaged 3.1 out of 5. All 62 women remained in the study through the end of the program, 97 percent of intervention sessions were completed and 92 percent of participants attended every session. These figures indicate that repeated self-reflection did not become an insurmountable burden for this group, although adherence could be different in populations facing greater financial, technological or caregiving constraints.

Participants did not use the skills uniformly. Willingness was reported on 44 percent of days with timely surveys, followed by time management on 31 percent and partner support on 30 percent. Engaging personal values appeared on 17 percent of days, while effective goal-setting was reported on only 3 percent during the main intervention period. The researchers suggest that willingness may have resonated because it matched the program’s rejection of an all-or-nothing approach and offered a direct response to low motivation. Time management and partner support addressed barriers commonly reported by women in midlife. Values-based strategies, by contrast, may have seemed more abstract and therefore less immediately actionable. Goal-setting may also have been understood as a weekly activity completed with a coach rather than a technique to use independently each day. By the three-month follow-up, however, goal-setting appeared on 22 percent of observed days, hinting that its role may shift as people move from adopting a behavior to maintaining it.

The data also revealed that skill use was highly dynamic, even within the same person. Depending on the skill, between 44 and 67 percent of the variation in daily reports reflected within-person fluctuation rather than stable differences between participants. In other words, a woman who used a strategy one day might not use it the next, likely because the circumstances she faced had changed. The average participant reported using 1.82 skills per day during the intervention and immediate follow-up, with daily totals ranging from zero to eight. The number of skills used increased as the program progressed, while the frequency of reported barriers declined by about 30 percent per week. Participants used slightly fewer skills on days when they attended intervention sessions than on days without sessions, perhaps because coaching days themselves structured activity or because participants had less time to apply additional strategies. The number of reported barriers, however, did not differ significantly between session and non-session days.

The strongest associations appeared when the researchers compared different days for the same participant. After controlling for each woman’s typical level of skill use and for the week of the intervention, every additional skill reported on a day corresponded to approximately 550 more steps. This was a within-person association, meaning the result compared a participant with herself across days rather than claiming that people who generally use more skills are inherently more active. Days without reported barriers were associated with about 2,000 more steps than days on which a barrier was reported. The relationship between skills and steps was even stronger on barrier days, suggesting that the strategies may have been most useful when movement was difficult. On days when barriers were present, participants used an average of 1.41 skills, compared with 2.23 on days without barriers, and they reported using no skills at all on 10 percent of barrier days. The study cannot establish that the skills caused the additional walking, but it identifies a plausible day-level pathway worth testing in controlled trials.

A smaller exploratory follow-up offered an early look at whether the tools survived beyond coaching. Of the 54 participants invited, 35 completed a seven-day assessment three months after the program, with surveys completed on time on 77 percent of expected days. Willingness and time management remained the most frequently reported skills. Goal-setting was more common than during the intervention, while problem-solving, cognitive defusion and communication were less frequent. Partner support fell from 30 percent of intervention days to 9 percent at follow-up, consistent with the loss of structured contact after the formal program ended. The researchers emphasize that this follow-up was optional and added after the study had begun, so participants who took part may have been especially engaged or may have benefited more from the intervention. Even so, the pattern suggests that some skills may become personally maintained practices, whereas others depend more heavily on coaching or social reinforcement.

The findings come with important limitations. This was a single-arm study without a control or attention-matched comparison group, so the investigators cannot determine whether the intervention itself caused the increase in skill use, the decline in barriers or the association with steps. The sample of 62 women limits the precision of between-person conclusions, and many participants had relatively high socioeconomic status and education. Step counts were obtained from different devices, including a study pedometer and personal Fitbit, Apple Watch, Garmin or Samsung monitors; participants also copied their step totals into the evening survey. Such measurement differences may introduce imprecision, although the researchers argue that consistent device-specific error within each participant would have less effect on within-person comparisons. The surveys measured whether a skill was used, not how skillfully or effectively it was applied. A higher number of skills might indicate a versatile toolkit, but it could also mean that participants had to try several strategies before one worked. Future studies should test specific skills and combinations, assess their quality and timing in real time, and include more diverse participants. For now, the study’s central message is less that everyone needs nine new techniques than that successful physical-activity programs may work best when they help people select practical responses to the barriers confronting them on a particular day.

The findings come from an observational study using two prospective population cohorts: 82,222 participants from the UK Biobank and 16,842 participants from the US National Health and Nutrition Examination Survey, or NHANES. The UK Biobank participants were drawn from dietary and health data collected between 2006 and 2010, while the NHANES analysis covered survey cycles from 2005 through 2018. Individuals with incomplete dietary information, missing outcome data, incomplete covariates or CKM stage 4—defined by established cardiovascular disease—were excluded. The researchers then followed participants through linked hospital and mortality records. Their primary cardiovascular endpoint, known as MACE, combined cardiovascular death, nonfatal myocardial infarction and stroke. All-cause mortality was also assessed, while NHANES analyses focused on mortality because reliable data on nonfatal cardiovascular events were unavailable.

CKM syndrome is designed to capture a continuum rather than a single diagnosis. Stage 0 describes people without recognized metabolic or kidney risk factors, while stage 1 includes elevated body mass index, increased waist circumference or prediabetes. Stage 2 incorporates conditions such as hypertension, diabetes, metabolic syndrome and moderate-to-high-risk chronic kidney disease. Stage 3 identifies people with very high-risk kidney disease or a predicted 10-year cardiovascular disease risk of at least 20 percent, even when overt cardiovascular disease has not yet been reported. This approach matters because metabolic dysfunction, kidney impairment and vascular injury often develop together for years before a heart attack or stroke occurs. Diet may influence that trajectory through several biological routes at once, including blood pressure, insulin sensitivity, lipid metabolism, oxidative stress and immune activation.

To measure diet quality, the investigators used different tools in the two cohorts because the available dietary data were not identical. The alternative Mediterranean diet, or AMED, score assessed nine components, rewarding higher intake of foods such as fruits, vegetables and whole grains while assigning reverse scores to red and processed meat and other less favorable components. The healthful plant-based diet index, or HPDI, divided foods into healthful plant foods, less healthful plant foods and animal-derived foods. Whole grains, fruits and vegetables received positive weights, whereas refined grains, sugary foods and animal foods received inverse weights. The researchers also calculated the Dietary Inflammatory Index, or DII, which estimates the inflammatory potential of a diet using as many as 45 food components. Positive scores indicate a more pro-inflammatory pattern, while negative scores indicate a more anti-inflammatory one. NHANES data allowed analysis of 28 components.

The associations were substantial but varied between measures and populations. In the UK Biobank, each standard-deviation increase in HPDI score was associated with a hazard ratio of 0.95 for MACE and 0.90 for all-cause mortality. For AMED, the corresponding hazard ratios were 0.93 for MACE and 0.90 for all-cause mortality. In practical terms, these estimates indicate roughly 5 to 10 percent lower relative risks for each standard-deviation improvement in the scores after adjustment for age, sex, ethnicity, education, socioeconomic status, smoking, alcohol use, physical activity, energy intake, body mass index and diabetes history. Compared with participants in the lowest score tertile, those in the highest HPDI and AMED tertiles had 11 percent and 13 percent lower risks of MACE, respectively. The study also linked higher HPDI scores to a 10 percent lower risk of cardiovascular death and a 6 percent lower risk of stroke, while higher AMED scores were associated with an 8 percent lower risk of cardiovascular death and a 9 percent lower risk of myocardial infarction.

The signal was especially clear for dietary inflammation. In NHANES, each standard-deviation increase in DII was associated with an 18 percent higher risk of both all-cause mortality and cardiovascular mortality. Compared with people in the lowest DII tertile, those in the highest had 38 percent higher all-cause mortality and 50 percent higher cardiovascular mortality. Conversely, each standard-deviation increase in AMED score was associated with a 12 percent reduction in all-cause mortality in NHANES. The researchers found no consistent nonlinear relationship between the dietary scores and mortality, myocardial infarction or cardiovascular death. However, HPDI showed an inverted U-shaped association with MACE, with scores above 60 linked to progressively lower risk, while AMED showed a U-shaped association with stroke. These patterns suggest that dietary effects may not increase in a simple straight line across the entire range of eating behaviors, although the study cannot determine an optimal score for individuals.

The analysis also examined individual vitamins and minerals, revealing a broad pattern of associations rather than a single “magic” nutrient. Higher intakes of alpha-carotene, beta-carotene and vitamin C were associated in both cohorts with lower risks of MACE, all-cause mortality and cardiovascular mortality. In the UK Biobank, participants in the highest alpha-carotene tertile had a 12 percent lower risk of stroke, while those with the highest beta-carotene intake had a 12 percent lower risk of myocardial infarction. Higher vitamin C intake was associated with a 20 percent reduction in cardiovascular mortality. In NHANES, greater intake of niacin, or vitamin B3, and folate, or vitamin B9, was associated with lower risks of all-cause and cardiovascular death. Vitamin E was associated with 9 percent lower all-cause mortality and 23 percent lower cardiovascular mortality for each standard-deviation increase in intake. Among minerals, higher copper, iron and magnesium intake was consistently associated with lower risks of MACE and mortality, with hazard ratios ranging from 0.63 to 0.89 when the highest and lowest intake tertiles were compared. Magnesium and copper were also linked to lower myocardial infarction risk, while zinc was associated with lower stroke risk.

The biological analyses offered clues about how diet might influence CKM outcomes. The researchers tested whether oxidative stress, inflammatory blood markers and phenotypic aging—an estimate of biological aging based on multiple biomarkers—could statistically mediate the diet-outcome associations. In the UK Biobank, phenotypic aging accounted for as much as 29.5 percent of the association between HPDI and MACE and 20.4 percent of the association between AMED and MACE. Oxidative stress measures, including uric acid and the uric-acid-to-HDL cholesterol ratio, accounted for portions ranging from 5.7 to 14.9 percent. White blood cell counts, neutrophils, lymphocytes and C-reactive protein also contributed to the statistical mediation, with proportions generally between 1.3 and 17 percent. In NHANES, uric acid, the uric-acid-to-HDL ratio and neutrophil counts partially mediated the relationships between AMED or DII and cardiovascular mortality. These results are compatible with the idea that plant-rich diets may reduce vascular risk partly by dampening chronic inflammation and oxidative damage while slowing biological aging, but mediation analysis in an observational study does not prove that these pathways are causal.

The researchers caution that the findings should be interpreted as evidence about dietary patterns and whole foods, not as a prescription for high-dose supplements. Nutrients are consumed together, and people who eat more fruits, vegetables, legumes and whole grains may also exercise more, smoke less, have greater access to health care or consume fewer ultra-processed foods. Although the statistical models adjusted for many of these factors, the study could not account for ultra-processed food intake, and the dietary assessments captured baseline habits rather than changes over time. Multiple vitamin and mineral comparisons were exploratory and were not formally corrected for multiple testing, raising the possibility that some associations occurred by chance. Dietary instruments also differed between the UK Biobank and NHANES, and NHANES participants who were excluded for missing information could have introduced selection bias. The analysis did not provide stage-specific guidance for CKM stages 0, 1, 2 and 3, and its participants came from two predominantly Western cohorts. Randomized dietary trials, especially those tracking inflammatory and aging biomarkers, will be needed to determine whether changing diet directly reduces cardiovascular events. For now, the evidence points toward a familiar but increasingly measurable strategy: emphasizing minimally processed plant foods, healthy fats, whole grains and nutrient-dense produce while limiting pro-inflammatory red and processed meat-based eating patterns may help interrupt CKM syndrome before it culminates in irreversible cardiovascular disease.

The investigators constructed a sophisticated lifetime simulation model integrating comprehensive datasets, notably the Systolic Blood Pressure Intervention Trial (SPRINT) and the National Health and Nutrition Examination Survey (NHANES), alongside meta-analytic inputs from the broader cardiovascular literature. The model projected long-term cardiovascular outcomes including incidences of myocardial infarction, ischemic stroke, and heart failure under different systolic blood pressure targets: less than 140 mm Hg, less than 130 mm Hg, and less than 120 mm Hg. Importantly, this analytical framework did not overlook the consequential spectrum of treatment-associated adverse events such as falls, acute kidney injury, hypotension, and bradycardia, thereby providing a balanced perspective on intensive antihypertensive therapy.

A critical innovation of this study lies in the explicit incorporation of real-world measurement inaccuracies in systolic blood pressure readings. Blood pressure measurement is notoriously prone to variability due to operator technique, device calibration, patient positioning, and biological fluctuations. By integrating these error rates observed in everyday clinical settings, the researchers added a vital layer of ecological validity to their cost-effectiveness analysis, ensuring that their findings remain applicable outside tightly controlled trial environments.

The simulation revealed that even when accounting for these common measurement errors, the aggressive target of <120 mm Hg consistently prevented a greater number of debilitating cardiovascular events compared to the more lenient <130 mm Hg target. This outcome signifies a paradigm shift, implying that achieving stringent blood pressure control confers profound long-term benefits that substantially outweigh the concerns raised by potential overtreatment or clinical measurement variability.

However, the intensification of therapy to reach the lowest systolic parameters was not without trade-offs. Adverse events related to intensified pharmacotherapy saw an uptick in the simulation, including an increased risk for falls in older adults—a clinically significant concern given the morbidity associated with fall-related fractures—alongside episodes of renal hypoperfusion manifesting as kidney injury, instances of symptomatic hypotension, and incidences of bradycardia. These nuances highlight the necessity for personalized clinical judgment, tailoring treatment intensity to the individual risk profiles and preferences of patients.

Economic considerations further enrich the study’s implications. While the <120 mm Hg treatment goal unavoidably increased healthcare utilization—reflected in greater antihypertensive drug consumption and more frequent clinical monitoring visits—cost-effectiveness analyses using quality-adjusted life years (QALYs) demonstrated the intervention’s value. Specifically, the cost per QALY gained at the intensive target was approximately $42,000, a figure well within commonly accepted thresholds for healthcare interventions, thereby affirming that tighter blood pressure control yields not only clinical but also economic benefits.

Karen Smith, PhD, an investigator at Brigham and Women’s Hospital and the study’s lead author, highlights the clinical confidence these findings should inspire. “Our data suggest that for patients at elevated cardiovascular risk, pursuing a systolic blood pressure target below 120 mm Hg is both clinically advantageous and economically rational,” Smith states. “This conclusion holds even under typical measurement error conditions, reinforcing the robustness of intensive blood pressure management strategies in real-world practice.”

Nevertheless, Smith cautions that the research focuses on population-level analysis and cost-effectiveness rather than individualized treatment recommendations. The increased incidence of adverse effects with more aggressive therapy means that “intensive blood pressure control will not be optimal for every patient.” She advocates for shared decision-making between clinicians and patients, emphasizing a nuanced appraisal of risks, benefits, and patient values when choosing an appropriate therapeutic target.

Additional contributors to the study include Thomas Gaziano, Alvin Mushlin, David Cutler, Nicolas Menzies, and Ankur Pandya, who collectively brought expertise in epidemiology, biostatistics, health economics, and clinical medicine to bear on this multifaceted investigation. The interdisciplinary nature of the research underscores the complexity inherent in balancing treatment intensity and adverse event risk in hypertension management, a challenge central to public health policy.

Funding for this important research was provided by the U.S. National Science Foundation and the National Institute of Neurological Disorders and Stroke, signaling robust support from leading scientific institutions dedicated to advancing cardiovascular health. Their involvement reinforces the study’s methodological rigor and relevance to national health priorities.

This publication arrives at a pivotal moment in cardiovascular medicine, where guidelines continue to evolve amid emerging evidence. By quantifying the real-world impact of intensive blood pressure targets and factoring in common clinical challenges such as measurement error and safety concerns, the study offers a comprehensive perspective that could influence future hypertension guidelines and inform clinical practice at large.

In conclusion, while intensified systolic blood pressure control to levels below 120 mm Hg comes with a nuanced risk-benefit profile, this research substantiates its superiority in preventing major cardiovascular events and offers a cost-effective strategy for managing high blood pressure. Importantly, these findings advocate for personalized therapeutic plans that consider patients’ unique clinical contexts and treatment goals, heralding a more refined approach to hypertension care in the years ahead.

Subject of Research: People
Article Title: Effect of systolic blood pressure measurement error on the cost-effectiveness of intensive blood pressure targets
News Publication Date: 18-Aug-2025
Web References: https://www.acpjournals.org/doi/10.7326/ANNALS-25-00560
References: Smith KC et al. “Effect of systolic blood pressure measurement error on the cost-effectiveness of intensive blood pressure targets” Annals of Internal Medicine DOI: 10.7326/ANNALS-25-00560
Keywords: Hypertension, Blood pressure, Cost effectiveness